Suniti Misra1, Shibnath Ghatak1, Alok Vyas2, Paul O'Brien3, Roger R Markwald1, Madhukar Khetmalas4, Vincent C Hascall5, James B McCarthy6, Nikos K Karamanos7, Markku I Tammi8, Raija H Tammi8, Glenn D Prestwitch9, Subhash Padhye2. 1. Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC 29425, USA. 2. ISTRA, Department of Chemistry, Abeda Inamdar College, University of Pune, Pune 411001, India. 3. Hematology/Oncology Division, Medical University of South Carolina, Charleston, SC 29425, USA. 4. Department of Bioinformatics and Computer Science, Dr. D. Y. Patil Biotechnology and Bioinformatics Institute, Dr. D. Y. Patil Vidyapeeth, Tathawade, Pune 411033, India. 5. Department of Biomedical Engineering/ND20, The Cleveland Clinic Foundation, Cleveland, OH, USA. 6. Department of Laboratory Medicine and Pathology, University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA. 7. Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece. 8. University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland. 9. Department of Medicinal Chemistry, University of Utah, Salt Lake City, UT, USA.
Abstract
Inflammatory pathway plays an important role in tumor cell progression of colorectal cancers. Although colon cancer is considered as one of the leading causes of death worldwide, very few drugs are available for its effective treatment. Many studies have examined the effects of specific COX-2 and 5-LOX inhibitors on human colorectal cancer, but the role of isothiocyanates (ITSCs) as COX-LOX dual inhibitors engaged in hyaluronan-CD44 interaction has not been studied. In the present work, we report series of ITSC analogs incorporating bioisosteric thiosemicarbazone moiety. These inhibitors are effective against panel of human colon cancer cell lines including COX-2 positive HCA-7, HT-29 cells lines, and hyaluronan synthase-2 (Has2) enzyme over-expressing transformed intestinal epithelial Apc10.1Has2 cells. Specifically, our findings indicate that HA-CD44v6-mediated COX-2/5-LOX signaling mediate survivin production, which in turn, supports anti-apoptosis and chemo-resistance leading to colon cancer cell survival. The over-expression of CD44v6shRNA as well as ITSC treatment significantly decreases the survival of colon cancer cells. The present results thus offer an opportunity to evolve potent inhibitors of HA synthesis and CD44v6 pathway and thus underscoring the importance of the ITSC analogs as chemopreventive agents for targeting HA/CD44v6 pathway.
Inflammatory pathway plays an important role in tumor cell progression of n class="Disease">colorectal cancers. Although colon cancer is considered as one of the leading causes of death worldwide, very few drugs are available for its effective treatment. Many studies have examined the effects of specific COX-2 and 5-LOX inhibitors on humancolorectal cancer, but the role of isothiocyanates (ITSCs) as COX-LOX dual inhibitors engaged in hyaluronan-CD44 interaction has not been studied. In the present work, we report series of ITSC analogs incorporating bioisosteric thiosemicarbazone moiety. These inhibitors are effective against panel of humancolon cancer cell lines including COX-2 positive HCA-7, HT-29 cells lines, and hyaluronan synthase-2 (Has2) enzyme over-expressing transformed intestinal epithelial Apc10.1Has2 cells. Specifically, our findings indicate that HA-CD44v6-mediated COX-2/5-LOX signaling mediate survivin production, which in turn, supports anti-apoptosis and chemo-resistance leading to colon cancer cell survival. The over-expression of CD44v6shRNA as well as ITSC treatment significantly decreases the survival of colon cancer cells. The present results thus offer an opportunity to evolve potent inhibitors of HA synthesis and CD44v6 pathway and thus underscoring the importance of the ITSC analogs as chemopreventive agents for targeting HA/CD44v6 pathway.
Authors: T D Camenisch; A P Spicer; T Brehm-Gibson; J Biesterfeldt; M L Augustine; A Calabro; S Kubalak; S E Klewer; J A McDonald Journal: J Clin Invest Date: 2000-08 Impact factor: 14.808
Authors: Ron N Apte; Shahar Dotan; Moshe Elkabets; Malka R White; Eli Reich; Yaron Carmi; Xiaping Song; Tatyana Dvozkin; Yakov Krelin; Elena Voronov Journal: Cancer Metastasis Rev Date: 2006-09 Impact factor: 9.264
Authors: Kostyantyn Krysan; Farrukh H Merchant; Li Zhu; Mariam Dohadwala; Jie Luo; Ying Lin; Nathalie Heuze-Vourc'h; Mehis Põld; David Seligson; David Chia; Lee Goodglick; Hejing Wang; Robert Strieter; Sherven Sharma; Steven Dubinett Journal: FASEB J Date: 2003-11-03 Impact factor: 5.191
Authors: Suniti Misra; Vincent C Hascall; Carla De Giovanni; Roger R Markwald; Shibnath Ghatak Journal: J Biol Chem Date: 2009-02-26 Impact factor: 5.157